UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of September 2019
Commission File Number:001-38281
ERYTECH Pharma S.A.
(Translation of registrant’s name into English)
60 Avenue Rockefeller
69008 Lyon France
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
Resignation of Director
ERYTECH Pharma S.A. (the “Company”) has announced that Allene Diaz has resigned from the Company’s Board of Directors, effective September 30, 2019. Ms. Diaz did not express any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Press Release
On September 17, 2019, the Company issued a press release regarding (i) Ms. Diaz’s resignation and (ii) a business update and financial results for the first half of 2019. A copy of the press release is attached to this Form6-K as Exhibit 99.1.
EXHIBIT LIST
Exhibit | Description | |
99.1 | Press Release dated September 17, 2019. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ERYTECH Pharma S.A. | ||||||
Date: September 18, 2019 | By: | /s/ Eric Soyer | ||||
Name | Eric Soyer | |||||
Title: | Chief Financial Officer and Chief Operating Officer |